AMSTERDAM, November 9, 2017 /PRNewswire/ --
Norgine B.V. today announced that it has expanded its partnership with Apharm s.r.l. by entering into an exclusive distribution deal for ZIVEREL(R) PLUS, a line extension of ZIVEREL(R). This deal expands on Norgine's existing collaboration with Apharm s.r.l. under which Norgine is distributing ZIVEREL(R) in Europe, Australia and New Zealand.
(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )
ZIVEREL(R) PLUS is a Class III medical device for the protective treatment of the oesophageal mucosa. ZIVEREL(R) PLUS additionally contains the antacid magaldrate and has been formulated to further enhance the protection and repair of the oesophagus, and to give even more rapid relief from the symptoms of gastroesophageal reflux than is already seen with ZIVEREL(R) . It is expected that ZIVEREL(R) PLUS will be launched in 2019.
Peter Martin, COO at Norgine said: "The addition of ZIVEREL(R) PLUS to our gastroenterology portfolio continues to demonstrate Norgine's strong expertise in commercialising transformative treatment options for patients who suffer from digestive diseases such as gastroesophageal reflux disease (GERD)." He added: "This new partnership continues to leverage the strong working relationship that Norgine has developed with Apharm and we are looking forward to launching the product in 2019."
Paolo Pizzoni, Managing Director of Apharm said: "We are pleased to expand our partnership with Norgine. This new development, building on the current ZIVEREL(R) formulation already successfully launched, is aimed to offer additional treatment options to patients with GERD."
Gastroesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.
ZIVEREL(R) is a non-reimbursed medical device, that does not require a medical prescription. Prices are applicable per country.
Contact: Isabelle Jouin, Telephone: +44(0)18958-26237